公开(公告)号：US12005115B2

公开(公告)日：2024-06-11

申请号：US16922322

申请日：2020-07-07

申请人： The USA, as represented by the Secretary, Dept. of Health and Human Services

发明人： Masaru Kanekiyo ,  Gary J. Nabel ,  Jeffrey Cohen ,  Wei Bu

IPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/08 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/085 ,  C12N7/00 ,  A61K2039/55505 ,  A61K2039/575 ,  A61K2039/64 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/735 ,  C12N2710/16222 ,  C12N2710/16234 ,  C12N2710/16271

摘要： Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.

公开(公告)号：US20200330587A1

公开(公告)日：2020-10-22

申请号：US16922322

申请日：2020-07-07

申请人： The USA, as represented by the Secretary, Dept. of Health and Human Services

发明人： Masaru Kanekiyo ,  Gary J. Nabel ,  Jeffrey Cohen ,  Wei Bu

IPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/08 ,  C12N7/00

摘要： Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.